Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer - PubMed
2 hours ago
- #pancreatic cancer
- #biomarkers
- #treatment monitoring
- DUPAN-2 serves as a surrogate biomarker for CA 19-9 nonexpressor pancreatic cancer patients.
- 5-10% of pancreatic cancer patients lack CA 19-9 expression, requiring alternative biomarkers.
- Achieving normal DUPAN-2 levels post-treatment correlates with improved overall and disease-free survival.
- DUPAN-2 dynamics mirror CA 19-9 patterns in expressors, showing similar reduction percentages.
- Routine DUPAN-2 monitoring may enable biomarker-guided decisions for previously unmonitored subgroups.